Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial.

Study Objectives: To assess the safety and efficacy of cabergoline in the treatment of idiopathic restless legs syndrome (RLS) patients.

Design: Open-label intervention study for 26 weeks; no control group.

Setting: 302 patients (73% women, aged 61 +/- 11 years) from 37 German neurologic outpatient departments and private practices.